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Creutzfeldt–Jakob disease is a rare, fatal, neurodegenerative disease caused by the accumulation of abnormally folded prion pro-
teins. The common polymorphism at codon 129 (methionine/valine) in the prion protein (PRNP) gene is the most important deter-
minant of genetic susceptibility. Homozygotes of either allele have a higher risk of sporadic Creutzfeldt–Jakob disease. Various
studies suggest that this polymorphism is also involved in other forms of dementia. We studied the association between the codon
129 polymorphism of the PRNP gene and mild cognitive impairment in 3605 participants from the Rotterdam Study using logistic
regression analyses. Subsequently, we studied the association between this polymorphism and incident dementia, including
Alzheimer’s disease, in 11 070 participants using Cox proportional hazard models. Analyses were adjusted for age and sex. We
found the prevalence of mild cognitive impairment to be higher for carriers of the methionine/methionine genotype (odds ratio,
1.40; 95% confidence interval, 1.11–1.78; P¼ 0.005) as well as for carriers of the valine/valine genotype (odds ratio, 1.37; 95%
confidence interval, 0.96–1.97; P¼0.08). The codon 129 polymorphism was not associated with the risk of incident dementia or
Alzheimer’s disease. In conclusion, we found a statistically significant higher prevalence of mild cognitive impairment in carriers of
the methionine/methionine genotype in the codon 129 polymorphism of the PRNP gene within this population-based study. No
associations were found between the codon 129 polymorphism and dementia or Alzheimer’s disease in the general population.
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Introduction
Creutzfeldt–Jakob disease is a rare, fatal, neurodegenerative
prion disease caused by the accumulation of abnormally
folded prion proteins. These proteins are the product of
the prion protein (PRNP) gene. In prion diseases, the cellu-
lar prion protein (PrPC) converts into a misfolded infectious
state, the pathological prion protein (PrPSc) (Prusiner,
1982). Creutzfeldt–Jakob disease occurs in different forms:
sporadic, genetic, iatrogenic, and variant. The sporadic
form of Creutzfeldt–Jakob disease is the most common
from. A major driver of the development and course of
sporadic Creutzfeldt–Jakob disease is a genetic variant at
codon 129 (methionine/valine) of the PRNP gene (Parchi
et al., 2012). Persons homozygous for either the methionine
or valine allele are at increased risk of sporadic
Creutzfeldt–Jakob disease (Alperovitch et al., 1999; Parchi
et al., 2009). It has been speculated that homozygosity for
either allele results in the synthesis of identical proteins,
enabling the propagation and aggregation of PRNP in the
brain, thus influencing both the risk and progression of
sporadic Creutzfeldt–Jakob disease (Alperovitch et al.,
1999; Parchi et al., 2009). Clinically, sporadic Creutzfeldt–
Jakob disease is characterized by rapidly progressive de-
mentia, and ultimately death on average 6 months after
diagnosis. The variant form of Creutzfeldt–Jakob disease is
the zoonotic form of the disease, which is transmitted
through meat and other food products contaminated with
material from cattle with bovine spongiform encephalop-
athy (Brandel et al., 2009). Up to 2017, all patients diag-
nosed with variant Creutzfeldt–Jakob disease had the
methionine/methionine (MM) genotype on PRNP codon
129. Recently, the first patient with the methionine/valine
(MV) genotype on PRNP codon 129 with the variant
form was reported (Mok et al., 2017).
While the dementia seen in Creutzfeldt–Jakob disease
patients is likely a result of prion protein aggregation,
various studies suggest that the PRNP gene is also
involved in other forms of dementia, but results are in-
consistent (Rujescu et al., 2003; Del Bo et al., 2006;
Jeong et al., 2007; Poleggi et al., 2008; Choi et al.,
2010; Golanska et al., 2013; He et al., 2013; Zhang
et al., 2016). Furthermore, studies performed on early
cognitive decline and early-onset Alzheimer’s disease also
show inconsistency regarding which of the homozygous
carriers have a higher risk (Croes et al., 2003; Dermaut
et al., 2003). In contrast, a meta-analysis on the role of
the M129V polymorphism in Alzheimer’s disease suggests
that individuals with at least one valine allele have a
lower risk of Alzheimer’s disease (He et al., 2013), while
the International Genetics of Alzheimer Disease Project
did not find an association (Kunkle et al., 2019).
In this study, we report on the association between the
PRNP M129V polymorphism and mild cognitive impair-
ment and dementia, including Alzheimer’s disease, within
the population-based Rotterdam Study.
Materials and methods
Setting and study population
The Rotterdam Study is a prospective population-based
middle-aged and elderly cohort that started in 1990 in
the district of Ommoord, in Rotterdam, The Netherlands.
The study includes 14 926 participants and has three
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subcohorts (Ikram et al., 2017). At start of the study, all
inhabitants of the district of Ommoord who were aged
55 years and older were invited to participate. At base-
line, in 1990–93, of the 10 215 invited inhabitants, 7983
agreed to participate in the baseline examination (re-
sponse rate 78%). In 2000, the cohort was extended
with 3011 participants (67% of invitees). This extension
consisted of all persons living in the study district who
had become 55 years and older or had moved into the
study district. A second extension was initiated in 2006,
in which 3932 participants (65% of invitees) who were
45 years and older were included. Study rounds consist of
a home interview and visits with extensive investigations
at the dedicated research centre. Rounds are repeated
every 4–6 years. Between 2002 and 2005 extensive neuro-
psychological tests were implemented in the Rotterdam
Study (de Bruijn et al., 2014). These tests are a require-
ment for the assessment of mild cognitive impairment.
Participants without contraindications are also invited to
undergo a brain MRI scan, which has been implemented
routinely since 2005, as discussed previously (Ikram
et al., 2015). Participants are continuously monitored for
diseases and mortality through linkage of the medical
records from the general practitioners and municipality
records. The Rotterdam Study has been approved by the
Medical Ethics Committee of the Erasmus MC and by
the Ministry of Health, Welfare and Sport of The
Netherlands. All participants provided written informed
consent to participate in the study and to obtain informa-
tion from their treating physicians.
Genotyping
A total of 11 496 participants who were genotyped
passed genotyping quality control (92% of all subjects
with genotyping) (Niemeijer et al., 2015). Exclusion crite-
ria were a call rate <98%, Hardy–Weinberg P-value
<106, minor allele frequency <0.01%, excess autosomal
heterozygosity >0.336, sex mismatch and outlying iden-
tity-by-state clustering estimates. Imputations were per-
formed using the Haplotype Reference Consortium panel
(Loh et al., 2016). We selected one single-nucleotide poly-
morphism within the PRNP gene: M129V. Imputation
quality for this single-nucleotide polymorphism was high
(r2 ¼ 0.97). We rounded the imputed single-nucleotide
polymorphism dosages to 0 (MM), 1 (MV) and 2 (val-
ine/valine (VV)).
Assessment of mild cognitive
impairment
We defined mild cognitive impairment using the following
criteria: (i) presence of subjective cognitive complaints, (ii)
presence of objective cognitive impairment and (iii) ab-
sence of dementia, as previously described (de Bruijn
et al., 2014). The first criterion, presence of subjective
cognitive complaints, was evaluated by an interview,
which consisted three questions on memory complaints
and three questions on impaired daily functioning. If the
participant confirmed the presence of one of these six
complaints or impairments, subjective cognitive com-
plaints were seen as present. The second criterion, pres-
ence of objective cognitive impairment, was assessed
using a cognitive test battery comprising letter digit test,
Stroop test, Purdue Pegboard test, fluency task and 15-
word verbal learning test based on Rey’s recall of words.
Participants were classified as objectively cognitive
impaired if they scored <1.5 standard deviation of the
age-adjusted and education-adjusted mean of the study
population. This has previously been explained in more
detail (de Bruijn et al., 2014). For this study, we included
participants with genetic data available and mild cogni-
tive impairment assessment during the implementation
period of extensive neuropsychological tests, as a large
number of participants were then screened for mild cog-
nitive impairment for the first time.
Assessment of dementia
Dementia ascertainment involved cognitive screening at
the study research centre. We further assessed individuals
with a Mini-Mental State Examination score of <26 or a
Geriatric Mental State Schedule organic level of >0 (de
Bruijn et al., 2015), by administering the Cambridge
Mental Disorders of the Elderly Examination by a re-
search physician. We also interviewed spouses or inform-
ants. A consensus panel headed by a consultant
neurologist established the final diagnosis according to
the standard criteria. We studied the outcomes of all-
cause dementia (DSM-III-R) and Alzheimer’s disease
(NINCDS–ADRDA). For the assessment of dementia, and
type of dementia, the latest follow-up information with
available data was used to determine the disease state.
Follow-up for dementia was near complete until 1
January 2015. Within this period, participants were cen-
sored at the date of dementia diagnosis, death or loss to
follow-up.
Brain MRI measurements
Brain MRI scanning was performed using a 1.5-T scan-
ner (General Electric Healthcare, Milwaukee, WI, USA),
and it included T1-weighted sequence, proton-density-
weighted sequence, fluid-attenuated inversion recovery-
weighted sequence and T2-weighted sequences (Ikram
et al., 2015). Details on methods for the measurement of
brain volume and hippocampal volume have been
described earlier (Ikram et al., 2015).
Statistical analysis
Logistic regression analyses were used to study the associ-
ation between the M129V polymorphism and mild cogni-
tive impairment. For mild cognitive impairment as
outcome of interest, analyses were conducted in all
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participants who had mild cognitive impairment assess-
ment at the implementation of neuropsychological tests.
Subsequently, the association between the M129V poly-
morphism and incident dementia, including incident
Alzheimer’s disease, was studied using Cox proportional
hazard models. For these two outcomes of interest, analy-
ses were conducted in all participants who had dementia
status and dementia type assessed. We ran the analyses
unadjusted (Model 1) and also while adjusting for age
and sex (Model 2). As secondary analyses, we ran linear
regression analyses to study the association between the
M129V polymorphism and MRI-derived brain volume
and hippocampal volume, while adjusting for age, sex
and intracranial volume.
Data availability statement
Because of restrictions based on privacy regulations and
informed consent of the participants, data cannot be
made freely available in a public repository. Data can be
obtained upon reasonable request. Requests for the
Rotterdam Study data should be directed towards the
management team (secretariat.epi@erasmusmc.nl).
Results
Descriptive statistics
We examined the 11 496 participants in the Rotterdam
Study who had genotyping data available from the
M129V polymorphism from the PRNP gene (Fig. 1). Of
these participants, 4991 (43.4%) had the MM genotype,
5209 (45.3%) had the MV genotype and the remaining
1295 (11.3%) had the VV genotype. The carriers of the
MM genotype tended to be slightly older than the two
other genotype groups. In the overall population, the dis-
tribution of this genotype was in Hardy–Weinberg equi-
librium. The general characteristics of the study
population are shown in Table 1.
PRNP M129V and the prevalence of
mild cognitive impairment
We found that carriers of the MM genotype have a
higher prevalence of mild cognitive impairment than
those who are heterozygous (odds ratio, 1.40; 95% confi-
dence interval, 1.11–1.78; P¼ 0.005), as shown in
Table 2. Carriers of the VV genotype showed a border-
line significant higher prevalence of mild cognitive impair-
ment than heterozygous carriers (odds ratio, 1.37; 95%
confidence interval, 0.96–1.97; P¼ 0.08). Combining
homozygous carriers (MM and VV) resulted in an odds
ratio of 1.40 (95% confidence interval, 1.11–1.75;
P¼ 0.004). The allele and genotype distribution of the
M129V polymorphism was not in Hardy–Weinberg equi-
librium in mild cognitive impairment cases. There was an
excess of homozygotes (both MM and VV carriers) in
the mild cognitive impairment cases.
PRNP M129V and other outcomes
We did not find significant evidence for the association
of PRNP M129V polymorphism with incident dementia,
including Alzheimer’s disease, as shown in Table 3. In
dementia and Alzheimer’s disease patients and controls,
the M129V polymorphism was in Hardy–Weinberg equi-
librium. We also did not find a significant association of
the M129V polymorphism with brain volume and hippo-
campal volume.
Discussion
In this study, we investigated the association of the
M129V polymorphism of the PRNP gene with mild cog-
nitive impairment and dementia. We found that homozy-
gous carriers had more often mild cognitive impairment
than heterozygous carriers. We did not find an associ-
ation between this polymorphism and dementia. We
found a significantly higher prevalence of mild cognitive
impairment in carriers of the MM genotype than in car-
riers of the MV genotype and a non-significant higher
prevalence of mild cognitive impairment in carriers of the
VV genotype than in carriers of the MV genotype. In
contrast, our results do not indicate a role of the M129V
polymorphism of the PRNP gene in dementia, including
Figure 1 Selection of subjects from the Rotterdam Study
population. Flowchart of the selection of the participants from
the Rotterdam Study.
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Alzheimer’s disease, nor in brain volume and hippocam-
pal volume. The mechanism underlying the association
between the M129V polymorphism of the PRNP gene
and neurodegeneration is thought to be caused by the ef-
fect the M129V polymorphism has on the aggregation of
pathological prion proteins in the brain. The aggregation
of pathological prion proteins is a biological process simi-
lar to the aggregation of tau protein and amyloid accu-
mulation (Walker, 2018), which are key features in
Alzheimer’s disease (Bloom, 2014).While most neurodege-
nerative diseases are known to involve more than one
misfolded or abnormally aggregated protein, a recent
study demonstrated prion protein aggregation to be an
independent pathogenic mechanism, with no cross-seeding
between prion protein and misfolded amyloid beta (Rossi
et al., 2019), although prion protein is a stress protein
that is elevated in (amyloid beta) plaques (Kellett and
Hooper, 2009). This suggests that the neurodegenerative
changes due to prion protein accumulation could occur
regardless of other ongoing neurodegenerative processes.
This could be a possible explanation for our finding that
the M129V polymorphism of the PRNP gene plays a
role in mild cognitive impairment, and not in dementia.
Our study showed that the M129V polymorphism of the
PRNP gene may increase the prevalence of mild cognitive
impairment. Mild cognitive impairment is often seen as
pre-stage of Alzheimer’s disease, related to apolipoprotein
E. This study showed the heterogeneity of mild cognitive
impairment as also other genes and other non-
Alzheimer’s disease dementing disorders are included in
the mild cognitive impairment population.
Several limitations in this study should be addressed.
Our analyses of the association of the M129V poly-
morphism with mild cognitive impairment have been per-
formed cross-sectionally. We were not able to calculate
the life-time risk of the M129V polymorphism on mild
cognitive impairment in the participants from our popula-
tion-based cohort study. Another potential limitation is
the generalizability of our findings, as our study was per-
formed in mainly Caucasians. Previous studies have
Table 2 Association of PRNP M129V polymorphism with mild cognitive impairment
Genotype Cases, n (%) Controls, n (%) Model 1 OR (95% CI) P Model 2 OR (95% CI) P
MM 182 (51) 1414 (44) 1.42 (1.13–1.80) 0.003 1.40 (1.11–1.78) 0.005
MV 133 (37) 1471 (45) 1.00 (reference) 1.00 (reference)
VV 45 (13) 360 (11) 1.38 (0.97–1.98) 0.08 1.37 (0.96–1.97) 0.08
Hardy–Weinberg equilibrium P: overall: 0.95, cases: 0.0099, controls: 0.44.
CI, confidence interval; MM, methionine/methionine; MV, methionine/valine; n, number of people; OR, odds ratio; VV, valine/valine.
Table 3 Risk of incident dementia, including Alzheimer’s disease, stratified on PRNP M129V polymorphism
Genotype Cases, n (%) Cohort at risk, n (%) Model 1 HR (95% CI) P Model 2 HR (95% CI) P
Dementia
MM 602 (43) 4802 (43) 1.01 (0.90–1.13) 0.89 1.01 (0.90–1.13) 0.90
MV 631 (44) 5015 (45) 1.00 (reference) 1.00 (reference)
VV 176 (13) 1253 (11) 1.12 (0.95–1.32) 0.18 1.16 (0.98–1.37) 0.09
Alzheimer’s disease
MM 480 (43) 4680 (44) 1.01 (0.89–1.15) 0.84 1.01 (0.87–1.15) 0.82
MV 500 (45) 4884 (45) 1.00 (reference) 1.00 (reference)
VV 125 (11) 1202 (11) 1.02 (0.84–1.24) 0.87 1.06 (0.87–1.29) 0.56
Hardy–Weinberg equilibrium P for dementia: overall: 0.30, cases: 0.59, controls: 0.19. Hardy–Weinberg equilibrium P for Alzheimer’s disease: overall: 0.18, cases: 0.76, controls:
0.19.
CI, confidence interval; HR, hazard ratio; MM, methionine/methionine; MV, methionine/valine; n, number of people; VV, valine/valine.
Table 1 Characteristics of the study population
Genotype at codon 129 of the prion protein gene P
MM MV VV
N 5 4991 N 5 5209 N 5 1296
Age at baseline, median (range) 63.2 (45.6–99.1) 62.6 (45.5–99.2) 62.6 (45.7–99.2) 0.06
Sex, female, n (%) 2878 (58) 3068 (59) 726 (56) 0.13
APOEe4 carrier, n (%)a 1377 (29) 1451 (29) 369 (30) 0.82
aFour percent of missings in each genotype group.
APOEe4, apolipoprotein E epsilon 4; n, number of people; N, number of people at risk; M, methionine; V, valine.
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studied the effect of the M129V polymorphism of the
PRNP gene in mild cognitive impairment and different
types of dementia in Asians (Jeong et al., 2007; Choi
et al., 2010; Zhang et al., 2016). No association was
found between the M129V polymorphism and mild cog-
nitive impairment in a Korean population (Choi et al.,
2010). Our findings are therefore not generalizable to
other ethnicities.
Our study also had several strengths. We used a popu-
lation-based cohort study, and our study had a relatively
large sample size. Although the sample size of the partici-
pants who underwent initial mild cognitive impairment
assessment was smaller than the overall sample with
available genotyping data and dementia assessment, we
had sufficient power to demonstrate the association be-
tween the M129V polymorphism and mild cognitive
impairment.
In conclusion, we found a statistically significant higher
prevalence of mild cognitive impairment in carriers of the
MM genotype in the M129V polymorphism of the
PRNP gene in the Rotterdam Study, but no associations
were found between this polymorphism and incidence of
dementia, including Alzheimer’s disease. Future studies
should further elucidate the role of the M129V poly-
morphism of the PRNP gene in cognitive function, de-
mentia and other neurodegenerative traits.
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